AusCann Group Holdings Limited (`AusCann' or `the Company') is announced that it has established a Medical Advisory Board (MAB) of leading clinicians in Australia, in the areas of pain, palliative care and geriatric medicine. Their remit is to provide independent and expert advice to assist in the development of novel product lines; the generation and evaluation of clinical evidence; and medical outreach activities. Dr Marc Russo, AusCann's Chief Medical Advisor, is the Chairperson of the newly established MAB. At the inaugural meeting, the MAB focused on defining key requirements for AusCann's real world data collection tool to assist prescribers in evaluating clinical outcomes for their individual patients and assessing clinical impact across patient cohorts. As a direct outcome of the meeting, AusCann is finalisingits advanced data management and analytics platform, previously announced in fiscal 2020. The platform is designed to meet the needs of Australian medicinal cannabis prescribers of AusCann's products. When finalised, the Company plans a pilot-scale launch of the platform before a national roll out across Australia. AusCann has also established a support programme for investigator-led research studies. In addition to conducting robust clinical trials, the data from research studies undertaken by independent investigators will expand the body of knowledge regarding the safety and effectiveness of the Company's products. AusCann has released this week its research web page, which includes a call for expressions of interest for relevant investigator-initiated studies (IIS). The Company will evaluate submissions received under its IIS programme for potential support including the provision of product and placebo for the trial.